The purpose of this report was to characterize the dynamics of the gene expression cascades induced by an IFN--1a treatment regimen in multiple sclerosis patients and to examine the molecular mechanisms potentially capable of causing heterogeneity in response to therapy. In this open-label pharmacodynamic study design, peripheral blood was obtained from eight relapsing-remitting multiple sclerosis patients just before and at 1, 2, 4, 8, 24, 48, 120, and 168 h after i.m. injection of 30 g of IFN--1a. The total RNA was isolated from monocyte-depleted PBL and analyzed using cDNA microarrays containing probes for>4000 known genes. IFN--1a treatment resulted in selective, time-dependent effects on multiple genes. The mRNAs for genes implicate...
Recent evidence indicates that single multiple sclerosis (MS) susceptibility genes involved in inter...
IFN-beta effectively controls clinical exacerbations and magnetic resonance imaging activity in most...
BACKGROUND: A relatively large proportion of relapsing-remitting multiple sclerosis (RRMS) patients ...
Multiple sclerosis (MS) is a heterogeneous disease. In order to understand the partial responsivenes...
Interferon-beta (IFNβ) is used to inhibit disease activity in multiple sclerosis (MS), but its mecha...
Abstract Background A substantial proportion of multiple sclerosis (MS) patients discontinue interfe...
Understanding the mechanisms that sustain the effects of disease modifying drugs in multiple scleros...
Objectives: To characterize the IFN1a-regulated gene expression on leukocytes of Multiple Sclerosi...
<div><p>The effects of interferon-beta (IFN-β), one of the key immunotherapies used in multiple scle...
Background: Interferon-beta (IFNb) is used to inhibit disease activity in multiple sclerosis (MS), b...
Background: Interferon (IFN) beta-1a is an approved treatment for relapsing remitting multiple scler...
Recent evidence indicates that single multiple sclerosis (MS) susceptibility genes involved in inter...
The aims of this study were to compare mRNA levels of melanoma differentiation-associated protein 5 ...
The aim of the study is the identification of genetic factors that influence the long-term response ...
The effects of interferon-beta (IFN-β), one of the key immunotherapies used in multiple sclerosis (M...
Recent evidence indicates that single multiple sclerosis (MS) susceptibility genes involved in inter...
IFN-beta effectively controls clinical exacerbations and magnetic resonance imaging activity in most...
BACKGROUND: A relatively large proportion of relapsing-remitting multiple sclerosis (RRMS) patients ...
Multiple sclerosis (MS) is a heterogeneous disease. In order to understand the partial responsivenes...
Interferon-beta (IFNβ) is used to inhibit disease activity in multiple sclerosis (MS), but its mecha...
Abstract Background A substantial proportion of multiple sclerosis (MS) patients discontinue interfe...
Understanding the mechanisms that sustain the effects of disease modifying drugs in multiple scleros...
Objectives: To characterize the IFN1a-regulated gene expression on leukocytes of Multiple Sclerosi...
<div><p>The effects of interferon-beta (IFN-β), one of the key immunotherapies used in multiple scle...
Background: Interferon-beta (IFNb) is used to inhibit disease activity in multiple sclerosis (MS), b...
Background: Interferon (IFN) beta-1a is an approved treatment for relapsing remitting multiple scler...
Recent evidence indicates that single multiple sclerosis (MS) susceptibility genes involved in inter...
The aims of this study were to compare mRNA levels of melanoma differentiation-associated protein 5 ...
The aim of the study is the identification of genetic factors that influence the long-term response ...
The effects of interferon-beta (IFN-β), one of the key immunotherapies used in multiple sclerosis (M...
Recent evidence indicates that single multiple sclerosis (MS) susceptibility genes involved in inter...
IFN-beta effectively controls clinical exacerbations and magnetic resonance imaging activity in most...
BACKGROUND: A relatively large proportion of relapsing-remitting multiple sclerosis (RRMS) patients ...